3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Fallopian Tube Neoplasms
5
Carcinoma, Ovarian Epithelial
4
Squamous Cell Carcinoma of Head and Neck
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Uterine Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Adenocarcinoma
2
Uterine Cervical Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcopenia
1
Salivary Gland Neoplasms
1
Recurrence
1
Primary Breast Cancer
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Neutropenia
1
Neoplasms, Unknown Primary
1
Neoplasms
1
NSCLC
1
Melanoma
1
Malnutrition
1
Head and Neck Neoplasms
1
Interventions
Cisplatin
90
Fluorouracil
76
Radiotherapy
63
Paclitaxel
58
Docetaxel
49
Oxaliplatin
48
Irinotecan
42
Leucovorin
32
Capecitabine
31
Carboplatin
27
Radiation
21
Surgical Procedures, Operative
20
Esophagectomy
20
pembrolizumab
15
Neoadjuvant Therapy
15
Bevacizumab
15
Cetuximab
13
Drug Therapy
12
Epirubicin
11
Chemotherapy, Adjuvant
9
S 1 (combination)
8
Magnetic Resonance Spectroscopy
8
Gemcitabine
8
Trastuzumab
7
Nivolumab
7
Erlotinib Hydrochloride
7
Surveys and Questionnaires
6
Panitumumab
6
Immunohistochemistry
6
Chemoradiotherapy
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Esophageal Neoplasms
×
CP protocol
×
Clear all
NCT01404156
2024-08-28
POWERRANGER
CancerCare Manitoba
Phase 2/3
Completed
29 enrolled